Century Therapeutics, Inc.

IPSC

NASDAQHealthcareBiotechnology

在 GoAI 中打開

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

47/ 100

GoAI評分

Hold

Wait — insufficient conviction to act

估值

Undervalued

動能

Neutral

情緒

Bearish

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Brent Pfeiffenberger
上市以來: 2021年6月18日
僱員: 78